Pro-Pharmaceuticals, Inc. (PRWP.OB) Receives First Order for DAVANAT® from Leading Pharmaceutical Company in Columbia, South America
Pro-Pharmaceuticals, Inc., a leader in the field of Galectin therapeutics engaged in the discovery, development and commercialization of therapeutics that target Galectin receptors for advanced treatment of cancer and fibrosis, recently announced that the company has received its first purchase order for DAVANAT® from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Earlier this year, Pro-Pharmaceuticals granted PROCAPS exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Under the terms of the agreement, PROCAPS is managing the approval process for DAVANAT® in Colombia. Pro-Pharmaceuticals received a purchase order for $200,000 from PROCAPS,…